Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1CNS 1

Conditions

Skin Neoplasms 1Plasmablastic Lymphoma 1Oligodendroglioma 1Melanoma 1Lymphomatoid Granulomatosis 1Lymphoma, Primary Effusion 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, B-Cell 1Lung Neoplasms 1Glioma 1Gallbladder Neoplasms 1Cholangiocarcinoma 1Carcinoma, Non-Small-Cell Lung 1Burkitt Lymphoma 1Astrocytoma 1

Interventions

Temozolomide 47Bevacizumab 41Radiotherapy 17Magnetic Resonance Spectroscopy 14Irinotecan 11Nivolumab 8Everolimus 7Radiation 6poly ICLC 5X-Rays 5Phantoms, Imaging 5Carboplatin 5pembrolizumab 4fluorodopa F 18 4Specimen Handling 4Nuclear Medicine Department, Hospital 4Granulocyte-Macrophage Colony-Stimulating Factor 4Erlotinib Hydrochloride 4Carmustine 4ribociclib 3palbociclib 3ivosidenib 3antineoplaston A10 3Vorinostat 3Radiotherapy, Intensity-Modulated 3Radiosurgery 3Modafinil 3Lomustine 3Biopsy 3veliparib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Glioma × varlilumab × Clear all
NCT02924038 2024-06-14

A Study of Varlilumab and IMA950 Vaccine Plus Poly-ICLC in Patients With WHO Grade II Low-Grade Glioma (LGG)

University of California, San Francisco

Phase 1 Terminated
14 enrolled 10 charts
CNSLymphoid

Astrocytoma, Glioma, Lymphoma, Follicular, Oligodendroglioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡